Form 4: Castle Biosciences CEO Executes Planned Stock Sale

CEO Derek Maetzold sold shares of Castle Biosciences common stock on June 15, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Summary

• CEO Derek Maetzold exercised options to acquire 550 shares at $2.39 per share.
• Following the exercise, the CEO sold a total of 3,894 shares at a weighted-average price of $20.66 per share.
• The transactions were executed across multiple family trusts and direct holdings.
• All sales were conducted under a Rule 10b5-1 trading plan adopted on December 3, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive financial management rather than a reaction to company-specific news.

Positives

• Transactions were executed under a pre-planned Rule 10b5-1 program, indicating systematic rather than reactive selling.
• The CEO maintains significant beneficial ownership across various trusts and direct holdings following the transaction.

Negatives

• The transaction represents a divestment of equity by the company's top executive.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity may signal ongoing planned divestment by insiders.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Management Comments

• The Reporting Person has committed to providing full information regarding the number of shares and prices at each trade level to the SEC, the issuer, or security holders upon request.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for executives to manage personal liquidity and tax obligations, and generally does not reflect a change in management's outlook on the company's fundamental business performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to avoid potential conflicts of interest or allegations of insider trading.
• The scale of the sale relative to the CEO's total holdings is consistent with typical executive wealth diversification strategies.

Related Party Transactions

• The filing discloses multiple transfers between the Reporting Person and various family trusts, including the Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Remainder Trusts.

Stakeholder Impact

• Minimal impact on shareholders as the sales were executed through a pre-arranged plan.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Castle Biosciences, CSTL, Insider Trading, Form 4, Derek Maetzold, Equity Compensation